CANNABIDIORCOL (CBD-C1)

If you thought CBD-C4 (cannabidibutol) was obscure, meet CBDC1 — cannabidiorcol. Where CBD-C4 has a four-carbon side chain, CBDC1 has just one. It is structurally the most stripped-down member of the cannabidiol homolog family, exists in cannabis only in trace concentrations, and has been studied by only a handful of research groups worldwide.

Yet the research that does exist on CBDC1 is genuinely interesting. Its primary mechanism — agonism at TRPV2 ion channels — places it in an important category of anti-inflammatory and potentially anticancer targets that are attracting growing interest in cannabinoid pharmacology. And patent filings from major pharmaceutical players suggest that “overlooked” does not mean “unimportant” (US Patent 12396963; New Phase Blends, 2023).

What Is CBDC1?

CBDC1 is the informal designation for cannabidiorcol (also written CBD-C1), a naturally occurring minor phytocannabinoid in the cannabis plant. Its other research designations include CBDO and O-1821. The CAS number is 35482-50-9, and its molecular formula is C₁₇H₂₂O₂ with a molecular weight of 258.36 g/mol (MedChemExpress, n.d.; Wikipedia contributors, 2025).

Structurally, CBDC1 is a homolog of CBD — sharing the same terpenophenolic core — but with the five-carbon (pentyl) side chain of CBD replaced by a single-carbon (methyl) group. This makes it the C1 member of the cannabidiol homolog series, at the extreme short end: CBD-C1 → CBD-C4 → CBD (C5) → CBDP (C7) in ascending chain length (New Phase Blends, 2023).

CBDC1 vs. CBD: Key Differences

The one-carbon side chain is not merely a chemical curiosity — it fundamentally changes CBDC1’s pharmacological behavior. The length of the alkyl side chain is the primary pharmacophore for cannabinoid receptor binding, and at just one carbon, CBDC1 has low affinity for both CB1 and CB2 receptors — the classical cannabinoid receptors that CBD itself engages only weakly (MedChemExpress, n.d.).

Instead of acting primarily through cannabinoid receptors, CBDC1’s pharmacological activity is centered on transient receptor potential (TRP) channels — particularly TRPV2. This represents a meaningfully different mechanism from CBD, not simply a weaker version of the same effects.

How CBDC1 Works: TRPV2 Channel Agonism

The transient receptor potential vanilloid type 2 (TRPV2) channel is a calcium-permeable ion channel expressed in immune cells, neurons, cardiac muscle, and various other tissues. It plays roles in inflammation, immune cell activation, pain sensing, and cell proliferation. TRPV2 is activated by high temperatures, mechanical stimuli, and certain chemical ligands — including cannabinoids (Lana et al., 2022).

CBDC1 (O-1821) is identified in the pharmacological literature specifically as a TRPV2 agonist. Through this mechanism, it has demonstrated anti-inflammatory effects in preclinical models — including reduction of matrix metalloproteinases (MMP-2 and MMP-3) involved in joint damage in rheumatoid arthritis fibroblast models (Talotti et al., 2021). The TRPV2 agonism mechanism also produces a nuanced dual profile: at therapeutic concentrations it is anti-inflammatory, but at high concentrations, TRPV2 activation has been associated with promotion of tumorigenesis through HSP70/27 and PI3K/Akt/mTOR signaling pathways — a dose-dependency that makes careful investigation important (MedChemExpress, n.d.).

What the Research Says

Rheumatoid Arthritis and Joint Inflammation

The most concrete preclinical evidence for CBDC1/O-1821 involves its activity in rheumatoid arthritis (RA) models. Research examining TRPV2 agonists — including O-1821 — found that they reduced expression of MMP-2 and MMP-3 in fibroblast-like synoviocytes from RA patients, and controlled severity of inflammation in animal arthritis models (Talotti et al., 2021). A 2023 study published in Clinical and Experimental Immunology demonstrated that combination therapy of a TRPV2 agonist with a TNF inhibitor achieved sustained suppression of disease severity and reduced joint damage in animal models (Laragione et al., 2023).

Neuroprotection and Ischemia

While this research centers on CBD rather than CBDC1 specifically, it illuminates the TRPV2 pathway that CBDC1 also acts through. A 2022 study demonstrated that CBD’s neuroprotective effects in an in vitro ischemia model were mediated at least in part by TRPV2 channel agonism — effects that were blocked when a TRPV2 antagonist was administered (Lana et al., 2022). Since CBDC1 acts on the same receptor, these findings are mechanistically relevant to its potential neuroprotective profile.

Anticancer Research

Molecular docking studies have investigated cannabidiorcol’s potential as an aromatase (CYP450) inhibitor — a mechanism of relevance to estrogen-dependent cancers including breast cancer. In silico screening found that cannabidiorcol, along with cannabidivarin (CBDV), exhibited among the best binding energies of the compounds tested in aromatase inhibition models (ResearchGate, n.d.). TRPV2 activation has also been implicated in glioblastoma multiforme cell proliferation inhibition, a mechanism shared with CBD (Lana et al., 2022). All anticancer findings are preclinical.

Pain Relief and Anti-Inflammatory Properties

The ortholog compound Δ9-tetrahydrocannabiorcol (C16) — the THC-family equivalent of CBDC1 — has been identified as antinociceptive at the spinal cord level through TRPA1 channel activation, without CB1 or CB2 receptor activity (PMC9722916, 2022). This parallel within the “orcol” cannabinoid family suggests that CBDC1’s shortened side chain may confer analgesic properties through TRP channels rather than classical cannabinoid receptor pathways.

Patent Activity and Pharmaceutical Interest

Despite the sparse published literature, CBDC1 has attracted formal pharmaceutical interest. A US patent (No. 12396963) claims cannabidiol-C1 (CBD-C1) for use as a medicament, describing data demonstrating efficacy in models of disease for the first time. The patent explicitly notes that prior to the invention, CBD-C1 “has not been shown to have any therapeutic effects” — making this an early-stage but formally filed claim of therapeutic utility (US Patent 12396963, n.d.).

This mirrors patent activity previously noted for CBD-C4 (cannabidibutol) and reflects a broader pharmaceutical strategy of characterizing and protecting minor cannabinoid homologs ahead of full clinical development.

Availability and Research Status

CBDC1 is not available as a consumer supplement. It is sold exclusively as an analytical reference standard (CAS 35482-50-9) for laboratory research at milligram quantities. Given its near-undetectable concentrations in cannabis, any research or pharmaceutical production would rely on synthetic manufacturing rather than extraction (New Phase Blends, 2023).

Its legal status in the United States mirrors other minor hemp-derived cannabinoids: it is not a scheduled substance federally, but it exists in a regulatory gray area given the FDA’s lack of specific guidance on minor cannabinoids in consumer products.

Frequently Asked Questions

The Bottom Line

CBDC1 (cannabidiorcol) is among the most obscure cannabinoids in the cannabis plant — a trace-level CBD homolog so minor that meaningful amounts can only be obtained synthetically. Its research profile is extremely limited, with no human clinical data and only a handful of preclinical or computational studies.

What makes it worth watching is its distinct pharmacological identity: low cannabinoid receptor affinity, primary activity through TRPV2 channel agonism, and early evidence of anti-inflammatory efficacy in joint disease models and aromatase-inhibitory activity in anticancer modeling. Patent filings staking a claim on its medicinal use suggest the pharmaceutical community sees enough potential to protect it. Whether that potential is ever fully developed will depend on future research that has yet to materialize.

Nothing in this article constitutes medical advice. Always consult a qualified healthcare provider before making any decisions about supplementation or treatment.

Back to List of Cannabinoids